Key Takeaways

  • Lineage advanced its investigational COR1 allogeneic corneal endothelial cell therapy into in vivo preclinical testing after achieving internal manufacturing milestones
  • The pluripotent stem cell-derived program aims to address limitations of donor-derived corneal endothelial cells, including supply constraints, donor variability, and short shelf life
  • Initial animal study data are expected later this year, while the company's manufacturing platform is intended to support large-scale, off-the-shelf production

Lineage Cell Therapeutics has advanced its COR1 allogeneic corneal endothelial cell (CEnC) transplant program into in vivo preclinical testing after meeting internal manufacturing and product characterization milestones, the company announced.

COR1 is an investigational pluripotent stem cell-derived corneal endothelial cell transplant being developed for the treatment of corneal endothelial disease. The program is designed to provide an allogeneic, off-the-shelf alternative to donor-derived corneal endothelial cells, which are currently approved for clinical use in Japan but remain constrained by limited donor availability, variability in tissue quality, complex processing requirements, and short shelf life.

According to Lineage, COR1 is being manufactured using its proprietary AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent cell Engineering) platform, which supports bioreactor-based expansion and differentiation of precursor cells. Lineage said it has established a thaw-and-inject formulation and achieved production of corneal endothelial cells that met its internal criteria for potency, identity, scalability, and consistency.

The company indicated these manufacturing achievements supported the decision to advance the program into animal studies, with initial in vivo data expected later this year.

Lineage also said its planned two-tier Good Manufacturing Practice (GMP) cell banking system could ultimately support production of millions of doses of the final COR1 product. In addition, the company reported that applying its AlloSCOPE 5D manufacturing process to the program is expected to improve manufacturing efficiency and reduce production costs through large-scale production.

"Millions of people are candidates for corneal transplants yet there is only one donor for every 70 diseased eyes globally," said Brian M. Culley, CEO of Lineage. "We believe we are well positioned to develop a consistent and off-the-shelf allogeneic source of CEnCs from our proprietary AlloSCOPE platform."

Mr. Culley noted that the approval of donor-derived corneal endothelial cell therapies in Japan provides clinical validation for the therapeutic approach while highlighting the opportunity to improve manufacturing consistency and expand access through a renewable cell source.